UW Carbone Cancer Center secures FDA go-ahead for Contralateral submandibular gland #msc injection for Pilot Study (NCT04489732) subjects, if interested, who have already received MSCs in one submandibular gland to treat radiation-induced xerostomia
A UW Program for Advanced Cell Therapy-enabled clinical trial (NCT04489732) in which autologous, interferon-γ stimulated, bone marrow-derived MSCs injected into one submandibular gland to treat patients with xerostomia caused by radiation therapy for head and neck cancer received FDA regulatory approval to inject MSCs into the other (contralateral) submandibular gland of study subjects interested in receiving this additional treatment. Randall Kimple MD, PhD, University of Wisconsin-Madison Associate Professor of Human Oncology is the Principal Investigator of this clinical trial titled where same dose (number) of MSCs that were injected into the first submandibular gland will be injected into the contralateral submandibular gland and the subjects will be followed for an additional 12 months.